xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT06024291</url>
    </required_header>
    <id_info>
      <org_study_id>EKNZ 2023-01345</org_study_id>
      <nct_id>NCT06024291</nct_id>
    </id_info>
    <brief_title>Reducing Circulating Sphingolipid Levels to Optimise Cardiometabolic Health - The SphingoFIT Trial</brief_title>
    <acronym>SphingoFIT</acronym>
    <official_title>Reducing Circulating Sphingolipid Levels to Optimise Cardiometabolic Health - The SphingoFIT Randomised Controlled Exercise Trial</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>University of Basel</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
      <collaborator>
        <agency>University of Lausanne</agency>
        <agency_class>Other</agency_class>
      </collaborator>
      <collaborator>
        <agency>Technical University of Munich</agency>
        <agency_class>Other</agency_class>
      </collaborator>
    </sponsors>
    <source>University of Basel</source>
    <oversight_info>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        The purpose of this study is to assess the effects of an 8-week supervised high-intensity&#xD;
        interval training (HIIT) program (vs. physical activity recommendations according to current&#xD;
        guidelines) on a comprehensive panel of circulating sphingolipids in middle-aged females and&#xD;
        males at elevated cardiometabolic risk.&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        Cardiometabolic diseases (CMD) account for about half of all deaths from non-communicable&#xD;
        diseases and are responsible for about one-third of all deaths worldwide. To combat the&#xD;
        growing burden of CMD on health systems, a shift towards more effective prevention and early&#xD;
        detection of these diseases is urgently needed.&#xD;
  &#xD;
        Blood lipids have been used since the middle of the last century to determine the risk of&#xD;
        developing CMD. Although classically used biomarkers such as cholesterol and triglycerides&#xD;
        provide acceptable risk assessment, there is increasing evidence that sphingolipids,&#xD;
        particularly ceramides, may allow improved risk assessment. Mechanistically, there is growing&#xD;
        data that sphingolipid accumulations lead to atherosclerosis and insulin resistance.&#xD;
  &#xD;
        To measure circulating sphingolipids in clinical practice, it is essential to provide&#xD;
        patients with evidence-based interventions that reduce sphingolipid levels and quantify the&#xD;
        reduction expected from such an intervention. Preliminary data suggest that regular physical&#xD;
        activity (PA), an effective, low-cost, and patient-empowering means of health optimisation,&#xD;
        may reduce sphingolipid levels.&#xD;
  &#xD;
        The current research project aims to explore whether and to what extent a fitness-enhancing&#xD;
        high-intensity interval training (HIIT) programme can lower circulating sphingolipid levels&#xD;
        in middle-aged individuals at elevated cardiometabolic risk (50% females). An 'omic-scale&#xD;
        sphingolipid profiling will be applied to capture the circulating sphingolipidome&#xD;
        comprehensively.&#xD;
  &#xD;
        Participants will be randomly allocated to either the intervention or the control group. The&#xD;
        exercise intervention will consist of an 8-week supervised HIIT (two walking- and one indoor&#xD;
        cycling-based session weekly). The control group will get PA recommendations based on current&#xD;
        guidelines.&#xD;
  &#xD;
        Maximal cardiopulmonary exercise testing (CPET) will be conducted on a cycle ergometer to&#xD;
        determine the VO2peak, peak heart rate and peak power output. After the 8-week training&#xD;
        programme, a second CPET will be performed to verify if the exercise intervention effectively&#xD;
        improved CRF. Body composition will be analysed before and after the 8-week intervention by&#xD;
        dual-energy x-ray absorptiometry and by bioelectrical impedance analysis.&#xD;
  &#xD;
        Trained medical staff will draw blood samples by venepuncture of the cubital fossa following&#xD;
        an overnight fast pre- and post-intervention. Planned blood analyses for basic&#xD;
        characterisation of risk factor profiles include total cholesterol, low-density lipoprotein&#xD;
        cholesterol (LDL) and high-density lipoprotein cholesterol (LDL), triglycerides, and HbA1c.&#xD;
        Glucose and insulin will also be measured to estimate insulin resistance using the HOMA-IR. A&#xD;
        high-coverage method using reversed-phase liquid chromatography coupled to tandem mass&#xD;
        spectrometry (RPLC-MS/MS) will be applied to quantify an extensive panel of circulating&#xD;
        sphingolipids (n=61).&#xD;
  &#xD;
        Retinal vessel diameters, a novel surrogate of microvascular health that responds positively&#xD;
        to exercise interventions, will be assessed pre- and post-intervention, and the brachial&#xD;
        artery FMD, which reflects endothelial function as an early marker of atherosclerotic&#xD;
        arterial damage.&#xD;
  &#xD;
        Each participant will receive individualised, pre-packaged meals for the two days preceding&#xD;
        blood sampling to minimise potential confounding. All participants will be fed to energy&#xD;
        balance. To monitor diet adherence, participants will be instructed to return all&#xD;
        non-consumed foods from the pre-packaged meals to the lab and take photos of additionally&#xD;
        consumed foods for later analysis.&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Not yet recruiting</overall_status>
    <start_date type="Anticipated">September 15, 2023</start_date>
    <completion_date type="Anticipated">September 15, 2025</completion_date>
    <primary_completion_date type="Anticipated">September 15, 2024</primary_completion_date>
    <phase>N/A</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>Randomized</allocation>
      <intervention_model>Parallel Assignment</intervention_model>
      <primary_purpose>Prevention</primary_purpose>
      <masking>Double (Participant, Investigator)</masking>
      <masking_description>As the randomisation will take place after the baseline examination, participants, exercise scientists, and physicians supervising the intervention will be blinded for group allocation at baseline but not post-intervention.</masking_description>
    </study_design_info>
    <primary_outcome>
      <measure>Concentration of circulating Cer16:0, Cer18:0, Cer24:0 and Cer24:1</measure>
      <time_frame>At baseline and after the 8-week intervention</time_frame>
      <description>Quantifying the changes in plasma level of the four sphingolipid species included in the ceramide-based scores (Cer16:0, Cer18:0, Cer24:0 and Cer24:1) following the 8-week HIIT programme (vs. physical activity recommendation).</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>Concentration of the other circulating sphingolipid species to be targeted</measure>
      <time_frame>At baseline and after the 8-week intervention</time_frame>
      <description>Quantifying the changes in plasma level of the other sphingolipids to be targeted following the 8-week HIIT programme (vs. physical activity recommendation).</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)</measure>
      <time_frame>At baseline and after the 8-week intervention</time_frame>
      <description>Quantifying the changes in HOMA-IR following the 8-week HIIT programme (vs. physical activity recommendation).</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Peak oxygen uptake (VO2peak)</measure>
      <time_frame>At baseline and after the 8-week intervention</time_frame>
      <description>Quantifying the changes in VO2peak following the 8-week HIIT programme (vs. physical activity recommendation).</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Retinal microvascular diameters</measure>
      <time_frame>At baseline and after the 8-week intervention</time_frame>
      <description>Quantifying the changes in retinal microvascular diameters following the 8-week HIIT programme (vs. physical activity recommendation).</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Brachial flow-mediated dilatation (FMD)</measure>
      <time_frame>At baseline and after the 8-week intervention</time_frame>
      <description>Quantifying the changes in FMD following the 8-week HIIT programme (vs. physical activity recommendation).</description>
    </secondary_outcome>
    <number_of_arms>2</number_of_arms>
    <enrollment type="Anticipated">98</enrollment>
    <condition>Overweight and Obesity</condition>
    <condition>Dyslipidemias</condition>
    <condition>Blood Pressure</condition>
    <condition>Cardiovascular Diseases</condition>
    <condition>Metabolic Disease</condition>
    <arm_group>
      <arm_group_label>HIIT group</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>The exercise intervention will consist of a supervised HIIT (two walking- and one indoor cycling-based session weekly), starting with a habituation week at an intensity of 75% of the maximal heart rate (HRmax). In the following seven weeks, the participants will perform a HIIT based on the following protocol and for a total duration of 45 min per session: warm-up for 10 min at 60%-70% HRmax followed by a high-intensity interval consisting of 4×4 min at 80%-95% HRmax with 3 min of active recovery at 60%-70% HRmax and a 10 min cool-down at 60%-70% HRmax. Heart rate will be monitored during training by Garmin HRM-Dual heart rate sensors combined with Garmin Forerunner 45S watches. Exercise scientists motivate the participants during the intervals and will control each participant's heart rate during and after every training session.</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Physical activity recommendation group</arm_group_label>
      <arm_group_type>Active Comparator</arm_group_type>
      <description>Asking physically inactive participants to maintain their inactive habits may not reflect realistic conditions and is no longer considered the best option in a randomised controlled exercise intervention. Indeed, most participants will be aware of the positive effects of PA - or will become aware of them during an exercise intervention study. Further, denying an exercise intervention to participants who would have benefited from it (for instance, participants at risk of cardiometabolic diseases) might be ethically questionable. In accordance with current practices, control group participants will be informed about the World Health Organization physical activity guidelines at the beginning of the study.</description>
    </arm_group>
    <intervention>
      <intervention_type>Other</intervention_type>
      <intervention_name>8-week HIIT programme</intervention_name>
      <description>See arm description</description>
      <arm_group_label>HIIT group</arm_group_label>
    </intervention>
    <intervention>
      <intervention_type>Other</intervention_type>
      <intervention_name>Physical activity recommendation</intervention_name>
      <description>See arm description</description>
      <arm_group_label>Physical activity recommendation group</arm_group_label>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            -  female or male sex,&#xD;
  &#xD;
            -  aged between 40 and 60 years,&#xD;
  &#xD;
            -  body mass index between 25.0 and 34.9 kg/m2,&#xD;
  &#xD;
            -  sedentary lifestyle, defined as not meeting the WHO guidelines on PA, i.e., at least&#xD;
               150 minutes of moderate-intensity aerobic PA per week as well as muscle-strengthening&#xD;
               activities on two or more days per week,&#xD;
  &#xD;
            -  medical clearance for HIIT by a study physician (including vital sign evaluation,&#xD;
               clinical examination, resting and exercise ECG),&#xD;
  &#xD;
            -  informed consent as documented by signature.&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            -  known pregnancy or breastfeeding,&#xD;
  &#xD;
            -  any current exercise-limiting musculoskeletal conditions of the lower limbs,&#xD;
  &#xD;
            -  any known current or chronic conditions limiting exhaustive exercise,&#xD;
  &#xD;
            -  known diabetes mellitus of any type,&#xD;
  &#xD;
            -  dyslipidaemia, if pharmaceutically treated,&#xD;
  &#xD;
            -  arterial hypertension ≥160/100 mmHg, pharmaceutically treated or not,&#xD;
  &#xD;
            -  any other known cardiovascular disease,&#xD;
  &#xD;
            -  known NASH,&#xD;
  &#xD;
            -  known macular degeneration, glaucoma, or high intraocular pressure (≥20 mm Hg),&#xD;
  &#xD;
            -  particular diet (vegetarian, vegan, lactose-free, gluten-free, or FODMAP-low diet&#xD;
               (ferment-able oligosaccharides, disaccharides, monosaccharides, and polyols),&#xD;
  &#xD;
            -  intake of glucagon-like peptide-1 analogues, orlistat or any weight-loss drug,&#xD;
  &#xD;
            -  inability to follow the procedures of the study, e.g., due to linguistic or cognitive&#xD;
               problems,&#xD;
  &#xD;
            -  concomitant involvement in another interventional trial or participation in another&#xD;
               interventional trial in the last four weeks.&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>40 Years</minimum_age>
      <maximum_age>60 Years</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <overall_official>
      <last_name>Arno Schmidt-Trucksäss, Prof, MD, MA</last_name>
      <role>Study Chair</role>
      <affiliation>Department of Sport, Exercise and Health, University of Basel, Basel, Switzerland</affiliation>
    </overall_official>
    <overall_contact>
      <last_name>Justin Carrard, MD</last_name>
      <phone>+41612074757</phone>
      <email>justin.carrard@unibas.ch</email>
    </overall_contact>
    <overall_contact_backup>
      <last_name>Luisa Prechtl, MD</last_name>
      <phone>+41612076872</phone>
      <email>luisa.prechtl@unibas.ch</email>
    </overall_contact_backup>
    <reference>
      <citation>Choi RH, Tatum SM, Symons JD, Summers SA, Holland WL. Ceramides and other sphingolipids as drivers of cardiovascular disease. Nat Rev Cardiol. 2021 Oct;18(10):701-711. doi: 10.1038/s41569-021-00536-1. Epub 2021 Mar 26.</citation>
      <PMID>33772258</PMID>
    </reference>
    <reference>
      <citation>Laaksonen R, Ekroos K, Sysi-Aho M, Hilvo M, Vihervaara T, Kauhanen D, Suoniemi M, Hurme R, Marz W, Scharnagl H, Stojakovic T, Vlachopoulou E, Lokki ML, Nieminen MS, Klingenberg R, Matter CM, Hornemann T, Juni P, Rodondi N, Raber L, Windecker S, Gencer B, Pedersen ER, Tell GS, Nygard O, Mach F, Sinisalo J, Luscher TF. Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol. Eur Heart J. 2016 Jul 1;37(25):1967-76. doi: 10.1093/eurheartj/ehw148. Epub 2016 Apr 28.</citation>
      <PMID>27125947</PMID>
    </reference>
    <reference>
      <citation>Tippetts TS, Holland WL, Summers SA. Cholesterol - the devil you know; ceramide - the devil you don't. Trends Pharmacol Sci. 2021 Dec;42(12):1082-1095. doi: 10.1016/j.tips.2021.10.001. Epub 2021 Nov 5.</citation>
      <PMID>34750017</PMID>
    </reference>
    <reference>
      <citation>Carrard J, Angst T, Weber N, Bienvenue J, Infanger D, Streese L, Hinrichs T, Croci I, Schmied C, Gallart-Ayala H, Hochsmann C, Koehler K, Hanssen H, Ivanisevic J, Schmidt-Trucksass A. Investigating the circulating sphingolipidome response to a single high-intensity interval training session within healthy females and males in their twenties (SphingoHIIT): Protocol for a randomised controlled trial. F1000Res. 2023 Aug 18;11:1565. doi: 10.12688/f1000research.128978.2. eCollection 2022.</citation>
      <PMID>37533665</PMID>
    </reference>
    <verification_date>August 2023</verification_date>
    <study_first_submitted>August 28, 2023</study_first_submitted>
    <study_first_submitted_qc>August 28, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">September 6, 2023</study_first_posted>
    <last_update_submitted>August 28, 2023</last_update_submitted>
    <last_update_submitted_qc>August 28, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">September 6, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Principal Investigator</responsible_party_type>
      <investigator_affiliation>University of Basel</investigator_affiliation>
      <investigator_full_name>Justin Carrard</investigator_full_name>
      <investigator_title>Postdoctoral researcher, Principal investigator</investigator_title>
    </responsible_party>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Cardiovascular Diseases</mesh_term>
      <mesh_term>Overweight</mesh_term>
      <mesh_term>Dyslipidemias</mesh_term>
      <mesh_term>Metabolic Diseases</mesh_term>
    </condition_browse>
    <patient_data>
      <sharing_ipd>No</sharing_ipd>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT06024291
  org study id: EKNZ 2023-01345
  nct id: NCT06024291
  lead sponsor: 
  collaborator: 
  collaborator: 
  is fda regulated drug: No
  is fda regulated device: No
  The purpose of this study is to assess the effects of an 8-week supervised high-intensity
        interval training (HIIT) program (vs. physical activity recommendations according to current
        guidelines) on a comprehensive panel of circulating sphingolipids in middle-aged females and
        males at elevated cardiometabolic risk.
  Cardiometabolic diseases (CMD) account for about half of all deaths from non-communicable
        diseases and are responsible for about one-third of all deaths worldwide. To combat the
        growing burden of CMD on health systems, a shift towards more effective prevention and early
        detection of these diseases is urgently needed.
  
        Blood lipids have been used since the middle of the last century to determine the risk of
        developing CMD. Although classically used biomarkers such as cholesterol and triglycerides
        provide acceptable risk assessment, there is increasing evidence that sphingolipids,
        particularly ceramides, may allow improved risk assessment. Mechanistically, there is growing
        data that sphingolipid accumulations lead to atherosclerosis and insulin resistance.
  
        To measure circulating sphingolipids in clinical practice, it is essential to provide
        patients with evidence-based interventions that reduce sphingolipid levels and quantify the
        reduction expected from such an intervention. Preliminary data suggest that regular physical
        activity (PA), an effective, low-cost, and patient-empowering means of health optimisation,
        may reduce sphingolipid levels.
  
        The current research project aims to explore whether and to what extent a fitness-enhancing
        high-intensity interval training (HIIT) programme can lower circulating sphingolipid levels
        in middle-aged individuals at elevated cardiometabolic risk (50% females). An 'omic-scale
        sphingolipid profiling will be applied to capture the circulating sphingolipidome
        comprehensively.
  
        Participants will be randomly allocated to either the intervention or the control group. The
        exercise intervention will consist of an 8-week supervised HIIT (two walking- and one indoor
        cycling-based session weekly). The control group will get PA recommendations based on current
        guidelines.
  
        Maximal cardiopulmonary exercise testing (CPET) will be conducted on a cycle ergometer to
        determine the VO2peak, peak heart rate and peak power output. After the 8-week training
        programme, a second CPET will be performed to verify if the exercise intervention effectively
        improved CRF. Body composition will be analysed before and after the 8-week intervention by
        dual-energy x-ray absorptiometry and by bioelectrical impedance analysis.
  
        Trained medical staff will draw blood samples by venepuncture of the cubital fossa following
        an overnight fast pre- and post-intervention. Planned blood analyses for basic
        characterisation of risk factor profiles include total cholesterol, low-density lipoprotein
        cholesterol (LDL) and high-density lipoprotein cholesterol (LDL), triglycerides, and HbA1c.
        Glucose and insulin will also be measured to estimate insulin resistance using the HOMA-IR. A
        high-coverage method using reversed-phase liquid chromatography coupled to tandem mass
        spectrometry (RPLC-MS/MS) will be applied to quantify an extensive panel of circulating
        sphingolipids (n=61).
  
        Retinal vessel diameters, a novel surrogate of microvascular health that responds positively
        to exercise interventions, will be assessed pre- and post-intervention, and the brachial
        artery FMD, which reflects endothelial function as an early marker of atherosclerotic
        arterial damage.
  
        Each participant will receive individualised, pre-packaged meals for the two days preceding
        blood sampling to minimise potential confounding. All participants will be fed to energy
        balance. To monitor diet adherence, participants will be instructed to return all
        non-consumed foods from the pre-packaged meals to the lab and take photos of additionally
        consumed foods for later analysis.
  allocation: Randomized
  intervention model: Parallel Assignment
  primary purpose: Prevention
  masking: Double (Participant, Investigator)
  masking description: As the randomisation will take place after the baseline examination, participants, exercise scientists, and physicians supervising the intervention will be blinded for group allocation at baseline but not post-intervention.
  measure: Concentration of circulating Cer16:0, Cer18:0, Cer24:0 and Cer24:1
  time frame: At baseline and after the 8-week intervention
  description: Quantifying the changes in plasma level of the four sphingolipid species included in the ceramide-based scores (Cer16:0, Cer18:0, Cer24:0 and Cer24:1) following the 8-week HIIT programme (vs. physical activity recommendation).
  measure: Concentration of the other circulating sphingolipid species to be targeted
  time frame: At baseline and after the 8-week intervention
  description: Quantifying the changes in plasma level of the other sphingolipids to be targeted following the 8-week HIIT programme (vs. physical activity recommendation).
  measure: Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)
  time frame: At baseline and after the 8-week intervention
  description: Quantifying the changes in HOMA-IR following the 8-week HIIT programme (vs. physical activity recommendation).
  measure: Peak oxygen uptake (VO2peak)
  time frame: At baseline and after the 8-week intervention
  description: Quantifying the changes in VO2peak following the 8-week HIIT programme (vs. physical activity recommendation).
  measure: Retinal microvascular diameters
  time frame: At baseline and after the 8-week intervention
  description: Quantifying the changes in retinal microvascular diameters following the 8-week HIIT programme (vs. physical activity recommendation).
  measure: Brachial flow-mediated dilatation (FMD)
  time frame: At baseline and after the 8-week intervention
  description: Quantifying the changes in FMD following the 8-week HIIT programme (vs. physical activity recommendation).
  arm group label: HIIT group
  arm group type: Experimental
  description: The exercise intervention will consist of a supervised HIIT (two walking- and one indoor cycling-based session weekly), starting with a habituation week at an intensity of 75% of the maximal heart rate (HRmax). In the following seven weeks, the participants will perform a HIIT based on the following protocol and for a total duration of 45 min per session: warm-up for 10 min at 60%-70% HRmax followed by a high-intensity interval consisting of 4×4 min at 80%-95% HRmax with 3 min of active recovery at 60%-70% HRmax and a 10 min cool-down at 60%-70% HRmax. Heart rate will be monitored during training by Garmin HRM-Dual heart rate sensors combined with Garmin Forerunner 45S watches. Exercise scientists motivate the participants during the intervals and will control each participant's heart rate during and after every training session.
  arm group label: Physical activity recommendation group
  arm group type: Active Comparator
  description: Asking physically inactive participants to maintain their inactive habits may not reflect realistic conditions and is no longer considered the best option in a randomised controlled exercise intervention. Indeed, most participants will be aware of the positive effects of PA - or will become aware of them during an exercise intervention study. Further, denying an exercise intervention to participants who would have benefited from it (for instance, participants at risk of cardiometabolic diseases) might be ethically questionable. In accordance with current practices, control group participants will be informed about the World Health Organization physical activity guidelines at the beginning of the study.
  intervention type: Other
  intervention name: 8-week HIIT programme
  description: See arm description
  arm group label: HIIT group
  intervention type: Other
  intervention name: Physical activity recommendation
  description: See arm description
  arm group label: Physical activity recommendation group
  criteria: 
  gender: All
  minimum age: 40 Years
  maximum age: 60 Years
  healthy volunteers: No
  last name: Arno Schmidt-Trucksäss, Prof, MD, MA
  role: Study Chair
  affiliation: Department of Sport, Exercise and Health, University of Basel, Basel, Switzerland
  last name: Justin Carrard, MD
  phone: +41612074757
  email: justin.carrard@unibas.ch
  last name: Luisa Prechtl, MD
  phone: +41612076872
  email: luisa.prechtl@unibas.ch
  citation: Choi RH, Tatum SM, Symons JD, Summers SA, Holland WL. Ceramides and other sphingolipids as drivers of cardiovascular disease. Nat Rev Cardiol. 2021 Oct;18(10):701-711. doi: 10.1038/s41569-021-00536-1. Epub 2021 Mar 26.
  PMID: 33772258
  citation: Laaksonen R, Ekroos K, Sysi-Aho M, Hilvo M, Vihervaara T, Kauhanen D, Suoniemi M, Hurme R, Marz W, Scharnagl H, Stojakovic T, Vlachopoulou E, Lokki ML, Nieminen MS, Klingenberg R, Matter CM, Hornemann T, Juni P, Rodondi N, Raber L, Windecker S, Gencer B, Pedersen ER, Tell GS, Nygard O, Mach F, Sinisalo J, Luscher TF. Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol. Eur Heart J. 2016 Jul 1;37(25):1967-76. doi: 10.1093/eurheartj/ehw148. Epub 2016 Apr 28.
  PMID: 27125947
  citation: Tippetts TS, Holland WL, Summers SA. Cholesterol - the devil you know; ceramide - the devil you don't. Trends Pharmacol Sci. 2021 Dec;42(12):1082-1095. doi: 10.1016/j.tips.2021.10.001. Epub 2021 Nov 5.
  PMID: 34750017
  citation: Carrard J, Angst T, Weber N, Bienvenue J, Infanger D, Streese L, Hinrichs T, Croci I, Schmied C, Gallart-Ayala H, Hochsmann C, Koehler K, Hanssen H, Ivanisevic J, Schmidt-Trucksass A. Investigating the circulating sphingolipidome response to a single high-intensity interval training session within healthy females and males in their twenties (SphingoHIIT): Protocol for a randomised controlled trial. F1000Res. 2023 Aug 18;11:1565. doi: 10.12688/f1000research.128978.2. eCollection 2022.
  PMID: 37533665
  responsible party type: Principal Investigator
  investigator affiliation: University of Basel
  investigator full name: Justin Carrard
  investigator title: Postdoctoral researcher, Principal investigator
  mesh term: Cardiovascular Diseases
  mesh term: Overweight
  mesh term: Dyslipidemias
  mesh term: Metabolic Diseases
  sharing ipd: No